News

Millions of Australians will pay up to 29% less for their Pharmaceutical Benefits Scheme (PBS) prescriptions because the maximum PBS co-payment is going down from $42.50 to $30. The co-payment for general scripts has decreased for the first time...

According to a survey of executives done by GlobalData Healthcare, the pharmaceutical industry's top concern heading into 2023 is INFLATION. The study, which was conducted between October 26 and November 23, found that CEOs ranked inflation as the biggest barrier...

Choosing the right specialist clinical software is essential for any healthcare organization. The software will help you manage your patients and their medical records and provide other important features. There are many software options on the market, so deciding...

Dysphagia is a condition that people can develop for a wide range of reasons. The main symptom of dysphagia is difficulties with swallowing foods and liquids. Being unable to swallow a lot of food can quickly become a problem...

Bruker Corporation and Switzerland-based Biognosys AG announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold...

ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc, the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of...

The molecular target for bone anabolic therapy has been discovered by a research team headed by Hong Kong Baptist University (HKBU), utilising a particular aptamer that acts as an inhibitor of sclerostin, a protein that inhibits bone development. In comparison...